U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06813534) titled 'IVUS Guided PCI in Patients With Chronic Kidney Disease' on May 09, 2023.
Brief Summary: The incidence of contrast-induced nephropathy (CIN) is high (> 25%) in patients with severe chronic renal disease (CKD) who undergo a percutaneous coronary procedure.
The development of CIN is a factor of poor prognosis and is associated with the occurrence of irreversible CKD, the need for dialysis, increased length of stay and hospital costs as well as the risk of death. There is no specific treatment for N-PCI, so its prevention is essential. Although many studies have been conducted to identify, compare and implement different pharmacologica...